OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance

Article summary

OS Therapies has completed the requalification of its OST-HER2 drug substance, enabling the company to proceed with regulatory submissions for early commercial access and a confirmatory Phase 3 trial.